Neuroadaptive responses to citalopram in rats using pharmacological magnetic resonance imaging

Psychopharmacology

Volumn 213, Issue 2-3, 2011, Pages 521-531

  Sekar, Sakthivel ^a   Verhoye, M ^c   Van Audekerke, J ^c   Vanhoutte, G ^c   Lowe, Andrew S ^d   Blamire, Andrew M ^b   Steckler, Thomas ^e   Van Der Linden, A ^c   Shoaib, Mohammed ^a,f  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

BOLD fMRI (phMRI); Brain; Citalopram; Medication development; SPM; SSRI antidepressants

Indexed keywords

CITALOPRAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD OXYGENATION; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; DRUG POTENTIATION; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HYPOTHALAMUS; LOW DRUG DOSE; MESENCEPHALON; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; RHOMBENCEPHALON;

ANIMALS; BRAIN; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; MAGNETIC RESONANCE IMAGING; MALE; OXYGEN; PIPERAZINES; PYRIDINES; RATS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 79952488228     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-2084-4     Document Type: Article

References (51)

1. Artigas F, Perez V, Alvarez E (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatr 51(3):248-251 (Pubitemid 24081512)
2. Blier P, de Montigny C, Chaput Y (1987) Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 7(6 Suppl):24S-35S, Review
3. Boorman L, Kennerley AJ, Johnston D, Jones M, Zheng Y, Redgrave P, Berwick J (2010) Negative blood oxygen level dependence in the rat: a model for investigating the role of suppression in neurovascular coupling. J Neurosci 30(12):4285-4294
4. Bosker FJ, Cremers TI, Jongsma ME, Westerink BH, Wikström HV, den Boer JA (2001) Acute and chronic effects of citalopram on postsynaptic 5-hydroxytryptamine(1A) receptor-mediated feedback: a microdialysis study in the amygdala. J Neurochem 76 (6):1645-1653 (Pubitemid 32221104)
5. Ceglia I, Acconcia S, Fracasso C, Colovic M, Caccia S, Invernizzi RW (2004) Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors. Br J Pharmacol 142(3):469-478 (Pubitemid 38869860)
6. Chan CK, Durieux ME (1997) Differential inhibition of lysophosphatidate signaling by volatile anesthetics. Anesthesiology 86(3):660-669 (Pubitemid 27118350)
7. Chen YC, Choi JK, Andersen SL, Rosen BR, Jenkins BG (2005) Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging. Psychopharmacology (Berl) 180(4):705-715 (Pubitemid 41317866)
8. Davidson RJ, Irwin W, Anderle MJ, Kalin NH (2003) The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatr 160:64-75
9. Davies J, Lloyd KR, Jones IK, Barnes A, Pilowsky LS (2003) Changes in regional cerebral blood flow with venlafaxine in the treatment of major depression. Am J Psychiatr 160:374-376 (Pubitemid 41110468)
10. Dixon AL, Prior M, Morris PM, Shah YB, Joseph MH, Young AM (2005) Dopamine antagonist modulation of amphetamine response as detected using pharmacological MRI. Neuropharmacology 48 (2):236-245 (Pubitemid 40208259)
11. Drevets WC, Bogers W, Raichle ME (2002) Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 12:527-544 (Pubitemid 35408704)
12. Friston KJ, Holmes AP, Worsley KJ, Poline J-B, Frith CD, Frackowiak RSJ (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2:189-210 (Pubitemid 124008664)
13. Geday J, Hermansen F, Rosenberg R, Smith DF (2005) Serotonin modulation of cerebral blood flow measured with positron emission tomography (PET) in humans. Synapse 55(4):224-229 (Pubitemid 40256304)
14. Gobert A, Rivet JM, Cistarelli L, Millan MJ (1997) Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100, 635 and GR 127, 935. J Neurochem 68(3):1159-1163 (Pubitemid 27086221)
15. Goodwin GM, De Souza RJ, Green AR (1987) Attenuation by electroconvulsive shock and antidepressant drugs of the 5-HT1A receptor-mediated hypothermia and serotonin syndrome produced by 8-OH-DPAT in the rat. Psychopharmacology (Berl) 91(4):500-505 (Pubitemid 17038216)
16. Gozzi A, Schwarz A, Reese T, Bertani S, Crestan V, Bifone A (2006) Region-specific effects of nicotine on brain activity: a pharmacologicalMRI study in the drug-naïve rat. Neuropsychopharmacology 31(8):1690-1703 (Pubitemid 44106700)
17. Hajnal JV, Myers R, Oatridge A, Schwieso JE, Young IR, Bydder GM (1994) Artifacts due to stimulus correlated motion in functional imaging of the brain. Magn Reson Med 31(3):283-291 (Pubitemid 24070943)
18. Hensler JG, Kovachich GB, Frazer A (1991) A quantitative autoradiographic study of serotonin1A receptor regulation. Effect of 5, 7-dihydroxytryptamine and antidepressant treatments. Neuropsychopharmacology 4(2):131-144
19. Hlustik P, Noll DC, Small SL (1998) Suppression of vascular artifacts in functional magnetic resonance images using MR angiograms. Neuroimage 7:224-231 (Pubitemid 28372792)
20. Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9(Suppl 1):19-26, Review
21. Jimmink A, Caminada K, Hunfeld NG, Touw DJ (2008) Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. Ther Drug Monit 30(3):365-371
22. Kalin NH, Davidson RJ, Irwin W, Warner G, Orendi JL, Sutton SK, Mock BJ, Sorenson JA, Lowe M, Turski PA (1997) Functional magnetic resonance imaging studies of emotional processing in normal and depressed patients: effects of venlafaxine. J Clin Psychiatr 58(Suppl 16):32-39
23. Kastrup A, Baudewig J, Schnaudigel S, Huonker R, Becker L, Sohns JM, Dechent P, Klingner C, Witte OW (2008) Behavioral correlates of negative BOLD signal changes in the primary somatosensory cortex. Neuroimage 41(4):1364-1371
24. Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, Arifuzzman AI, Houle S, Vaccarino FJ (2001) Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatr 158:899-905 (Pubitemid 32547619)
25. Kia HK, Brisorgueil MJ, Hamon M, Calas A, Vergé D (1996) Ultrastructural localization of 5-hydroxytryptamine1A receptors in the rat brain. Neurosci Res 46(6):697-708
26. Leslie RA, James MF (2000) Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol Sci 21(11):422-423
27. Littlewood CL, Jones N, O'Neill MJ, Mitchell SN, Tricklebank M, CR WS (2006) Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology 186:64-81 (Pubitemid 43668312)
28. Logothetis NK, Wandell BA (2004) Interpreting the BOLD signal. Annu Rev Physiol 66:735-769 (Pubitemid 40614461)
29. Loubinoux I, Pariente J, Rascol O, Celsis P, Chollet F (2002) Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. Neuropsychologia 40(11):1815-1821
30. Lowe AS, Williams SCR, Symms MR, Stolerman IP, Shoaib M (2002) Functional magnetic resonance neuroimaging of drug dependence: naloxone-precipitated morphine withdrawal. Neuroimage 17:902-910 (Pubitemid 35317023)
31. Lowe AS, Beech JS, Williams SCR (2007) Small animal, whole brain fMRI: innocuous and nociceptive forepaw stimulation. Neuroimage 35:719-728 (Pubitemid 46420429)
32. Lowe AS, Barker Gareth J, Beech John S, Ireland Matthew D, Williams Steve CR (2008) A method for removing global effects in small-animal functional MRI. NMR Biomed 21:53-58 (Pubitemid 351227753)
33. Matos FF, Urban C, Yocca FD (1996) Serotonin (5-HT) release in the dorsal raphé and ventral hippocampus: raphé control of somatodendritic and terminal 5-HT release. J Neural Transm 103(1-2):173-190
34. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA (2000) Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatr 48:830-843
35. McKie S, Del-Ben C, Elliott R, Williams S, del Vai N, Anderson I, Deakin JF (2005) Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl) 180(4):680-686 (Pubitemid 41317864)
36. Muraki I, Inoue T, Koyama T (2008) Effect of co-administration of the selective 5-HT1A receptor antagonist WAY 100, 635 and selective 5-HT1B/1D receptor antagonist GR 127, 935 on anxiolytic effect of citalopram in conditioned fear stress in the rat. Eur J Pharmacol 586(1-3):171-178
37. Nierenberg AA, Ostacher MJ, Huffman JC, Ametrano RM, Fava M, Perlis RH (2008) A brief review of antidepressant efficacy, effectiveness, indications and usage for major depressive disorder. J Occup Environ Med 50(4):428-436 (Pubitemid 351521617)
38. O'Hearn E, Molliver ME (1984) Organization of raphe-cortical projections in rat: a quantitative retrograde study. Brain Res Bull 13(6):709-726 (Pubitemid 15090392)
39. Pacher P, Kecskeméti V (2004) Cardiovascular effects of selective serotonin reuptake inhibitor antidepressants. Orv Hetil 145 (8):425-431, Review
40. Plenge P, Mellerup ET (2003) Pindolol and the acceleration of the antidepressant response. J Affect Disord 75(3):285-289 (Pubitemid 36860032)
41. Preece M, Mukherjee B, Huang CL, Hall LD, Leslie RA, James MF (2001) Detection of pharmacologically mediated changes in cerebral activity by functional magnetic resonance imaging: the effects of sulpiride in the brain of the anaesthetized rat. Brain Res 916(1-2):107-114 (Pubitemid 32971911)
42. Rose EJ, Simonotto E, Spencer EP, Ebmeier KP (2006) The effects of escitalopram on working memory and brain activity in healthy adults during performance of the n-back task. Psychopharmacology (Berl) 185(3):339-347
43. Schridde U, Khubchandani M, Motelow JE, Sanganahalli BG, Hyder F, Blumenfeld H (2008) Negative BOLD with large increases in neuronal activity. Cerebr Cortex 18(8):1814-1827 (Pubitemid 352019902)
44. Seifritz E, Baumann P, Müller MJ, Annen O, Amey M, Hemmeter U, Hatzinger M, Chardon F, Holsboer-Trachsler E (1996) Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 14(4):253-263
45. Sharp T, Umbers V, Gartside SE (1997) Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br J Pharmacol 121(5):941-946 (Pubitemid 27277788)
46. Shoaib M, Lowe AS, CR WS (2004) Imaging localised dynamic changes in the nucleus accumbens following nicotine withdrawal in rats. Neuroimage 22:847-854 (Pubitemid 38759448)
47. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1997) The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897-916
48. Van de Kar LD (1991) Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Annu Rev Pharmacol Toxicol 31:289-320, Review
49. Verge D, Daval G, Marcinkiewicz M, Patey A, el Mestikawy S, Gozlan H, Hamon M (1986) Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5, 7-dihydroxytryptamine-treated rats. J Neurosci 6(12):3474-3482
50. Weikop P, Kehr J, Scheel-Krüger J (2007) Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors. J Psychopharmacol 21 (8):795-804 (Pubitemid 350029186)
51. Wingen M, Kuypers KP, Ramaekers JG (2007) Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI. J Psychopharmacol 21(5):477-485 (Pubitemid 47106923)